Lapatinib
Side effects
Options:
Show MedDRA Preferred Terms
|
Side effect
|
Data for drug
|
Placebo
|
Labels
|
|
|
1
|
2
|
3
|
|
Arthralgia
|
very common
|
|
|
x
|
|
|
Dehydration
|
very common
|
|
|
x
|
x
|
|
Dermatitis
|
very common
|
|
|
|
x
|
|
Fatigue
|
very common, 0% - 21%
|
|
x
|
x
|
x
|
|
Neuropathy peripheral
|
very common
|
|
|
|
x
|
|
Dermatitis acneiform
|
very common
|
|
x
|
x
|
|
|
Hot flush
|
very common
|
|
|
x
|
|
|
Abdominal pain
|
very common, 12%
|
|
|
x
|
x
|
|
Mucosal inflammation
|
very common, 0% - 12%
|
|
x
|
x
|
x
|
|
Neutropenia
|
5% - 47%
|
|
|
|
x
|
|
Constipation
|
common, very common
|
|
|
x
|
x
|
|
Diarrhoea
|
very common, 0% - 40%
|
|
x
|
x
|
x
|
|
Hyperbilirubinaemia
|
common, very common
|
|
|
x
|
x
|
|
Anorexia
|
very common, 0% - 18%
|
|
x
|
x
|
x
|
|
Asthenia
|
very common, 0% - 11%
|
|
x
|
x
|
x
|
|
Stomatitis
|
very common, 0% - 11%
|
|
x
|
x
|
x
|
|
Nausea
|
very common, 0% - 43%
|
|
x
|
x
|
x
|
|
Leukopenia
|
1% - 33%
|
|
|
|
x
|
|
Alopecia
|
very common, 0% - 7%
|
|
x
|
x
|
x
|
|
Rash
|
very common, 0% - 24%
|
|
x
|
x
|
x
|
|
Pain in extremity
|
very common, 0% - 7%
|
|
x
|
x
|
x
|
|
Back pain
|
very common, 0% - 6%
|
|
x
|
x
|
x
|
|
Insomnia
|
very common, 0% - 6%
|
|
x
|
x
|
x
|
|
Dyspnoea
|
very common, 0% - 8%
|
|
x
|
x
|
x
|
|
Headache
|
common — 0% - 13%
|
|
x
|
x
|
x
|
|
Paronychia
|
postmarketing, common
|
|
x
|
x
|
x
|
|
Peripheral sensory neuropathy
|
5%
|
|
|
|
x
|
|
Dry skin
|
very common, 0% - 6%
|
|
x
|
x
|
x
|
|
Myalgia
|
very common, 0% - 10%
|
|
|
|
x
|
|
Hepatotoxicity
|
common
|
|
x
|
x
|
x
|
|
Left ventricular ejection fraction decreased
|
common
|
|
|
x
|
x
|
|
Cough
|
very common, 0% - 9%
|
|
|
x
|
x
|
|
Pruritus
|
very common, 0% - 9%
|
|
x
|
x
|
x
|
|
Anaemia
|
0% - 10%
|
|
|
|
x
|
|
Dyspepsia
|
very common, 0% - 3%
|
|
x
|
x
|
x
|
|
Vomiting
|
very common, 0% - 21%
|
|
x
|
x
|
x
|
|
Pneumonia
|
uncommon
|
|
x
|
x
|
x
|
|
Interstitial lung disease
|
uncommon
|
|
x
|
x
|
x
|
|
Epistaxis
|
very common, 0% - 2%
|
|
x
|
x
|
x
|
|
Alanine aminotransferase increased
|
0% - 8%
|
|
|
|
x
|
|
Haemoglobin decreased
|
0% - 2%
|
|
|
|
x
|
|
Nail disorder
|
postmarketing — 0% - 2%
|
|
x
|
x
|
x
|
|
Anaphylactic shock
|
postmarketing, rare
|
|
x
|
x
|
x
|
|
Hypersensitivity
|
postmarketing, rare
|
|
x
|
x
|
x
|
|
Immune system disorder
|
postmarketing
|
|
x
|
x
|
x
|
|
Unspecified disorder of skin and subcutaneous tissue
|
postmarketing
|
|
x
|
x
|
x
|
|
Mental disorder
|
|
|
x
|
x
|
x
|
|
Neoplasm malignant
|
|
|
x
|
x
|
x
|
|
Infection
|
|
|
x
|
|
|
|
Connective tissue disorder
|
|
|
x
|
x
|
x
|
|
Gastrointestinal disorder
|
|
|
x
|
x
|
x
|
|
Cardiac disorder
|
|
|
|
x
|
x
|
|
Cardiac failure
|
|
|
|
x
|
x
|
|
Blood disorder
|
|
|
|
|
x
|
|
Renal failure acute
|
|
|
|
x
|
|
|
Mediastinal disorder
|
|
|
x
|
x
|
x
|
|
Nervous system disorder
|
|
|
x
|
x
|
x
|
|
Palpitations
|
|
|
|
x
|
x
|
|
Angiopathy
|
|
|
|
x
|
|
|
Malnutrition
|
|
|
|
x
|
x
|
|
Decreased appetite
|
0% - 19%
|
|
|
|
x
|
|
Hepatobiliary disease
|
|
|
|
x
|
x
|
|
Blood bilirubin increased
|
|
|
|
|
x
|
|
Infestation NOS
|
|
|
x
|
|
|
|
Blood and lymphatic system disorders
|
|
|
|
|
x
|
|
Cardiotoxicity
|
|
|
x
|
x
|
|
|
Metastatic disease
|
|
|
x
|
|
|
Indications
Information about indications was extracted from the indications and usage sections of the labels.
| Side effects: | 39 |
|---|
| Source: | FDA Structured Product Label |
|---|
| Side effects: | 51 |
|---|
| Source: | EMA |
|---|
| Side effects: | 58 |
|---|
| Source: | medicines.org.au |
|---|
Color scheme:
standard – alternative
|
|
|
100%
|
|
|
|
75%
|
|
|
|
50%
|
|
|
|
10%
|
|
|
|
frequent (1% to 100%)
|
|
|
|
infrequent (0.1% to 1%)
|
|
|
|
rare (<0.1%)
|
|
|
|
postmarketing
|
|
|
|
0%
|
|
|
|
no frequency information
|
|
|
|
not found on label
|
